Myositis News and Research RSS Feed - Myositis News and Research

Myositis is inflammation of your skeletal muscles, which are also called the voluntary muscles. These are the muscles you consciously control that help you move your body. An injury, infection or autoimmune disease can cause myositis. The diseases dermatomyositis and polymyositis both involve myositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Both diseases are usually treated with prednisone, a steroid medicine, and sometimes other medicines.
Anti-TNF therapy offers new hope to JDM patients

Anti-TNF therapy offers new hope to JDM patients

The results of a UK study presented today at the European League Against Rheumatism Annual Congress showed that tumour necrosis factor inhibitor (anti-TNF) treatment is effective at improving both muscle and skin involvement in children with juvenile dermatomyositis (JDM). [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death. [More]
FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans. [More]

Former all-American wrestler speaks about his personal battle with chronic muscle disease

In 2009, Mike Powell was where he'd always wanted to be. A former all-American wrestler himself, he'd returned to his Chicago-area high school to become the toughest wrestling coach around, inspiring young athletes with a brutal mix of love and punishing workouts. [More]
Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]
Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3. [More]
New antibody could boost strength, muscle mass in patients with cancer and other diseases

New antibody could boost strength, muscle mass in patients with cancer and other diseases

A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology. [More]
GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%. [More]
Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer. [More]
Cancer triggers scleroderma, shows evidence

Cancer triggers scleroderma, shows evidence

Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage. [More]
Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

Researchers from major universities in the U.S. have developed specific tests to identify cancer biomarkers in patients with dermatomyositis-a systemic inflammatory disease associated with increased risk of malignancy. [More]
FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

Milo Biotechnology today announced its AAV1-FS344 has been granted Orphan Drug designation from the FDA's Office of Orphan Products Development for treatment of Becker and Duchenne muscular dystrophy. AAV1-FS344 is a gene therapy-delivered myostatin inhibitor that increases muscle strength. [More]
FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults. [More]
DYNC1H1 genetic mutation contributes to SMA-LED

DYNC1H1 genetic mutation contributes to SMA-LED

Scientists have confirmed that mutations of a gene are responsible for some cases of a rare, inherited disease that causes progressive muscle degeneration and weakness: spinal muscular atrophy with lower extremity predominance, also known as SMA-LED. [More]
Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection. [More]
Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting. [More]
Advertisement
Advertisement